Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00152503 · ClinicalTrials.gov registry record · Phase 2
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
A Phase 2 study of Epilepsy, Partial, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 17
- Study locations
NCT00152503: Completed Phase 2 study of Epilepsy, Partial, sponsored by UCB Pharma.
NCT00152503 is a Phase 2 study of Epilepsy, Partial that has completed, run by UCB Pharma. The registered enrollment target is 59 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). The trial reports 17 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00152503, a Phase 2 study of Epilepsy, Partial, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 17
- Study locations
Study Summary
This trial will evaluate the efficacy and safety of UCB44212 as add-on therapy in subjects with focal epilepsy.
Primary Outcome
Calculated as (7-day seizure frequency during the Treatment Period) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)), divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial onset seizure frequency from Baseline. The Treatment Period consists of an 8-week Up-Titration Period (Visit 3/Week 5 to Visit 7/Week 12) and a 3-week Down-Titration Perio
Conditions Studied
Interventions
- DRUG Seletracetam (UCB44212)
Study Locations (17)
Ohio
- - Cincinnati
- - Columbus
Other
- - Calgary
- - Montreal
Arizona
- - Phoenix
Arkansas
- - Little Rock
Florida
- - St. Petersburg
Illinois
- - Springfield
Kansas
- - Wichita
Michigan
- - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2005-08-31 |
| Est. Completion | 2006-05-12 |
| Phase | Phase 2 |
What the finished NCT00152503 record still lists
NCT00152503 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Epilepsy, Partial appearing as the primary indexed condition, and to 1 intervention - of which Seletracetam (UCB44212) is the first listed.
NCT00152503 lists 17 locations in 15 states (Ohio, Other, Arizona).
Frequently Asked Questions
What is clinical trial NCT00152503 about?
NCT00152503 is a clinical study titled "Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam". This trial will evaluate the efficacy and safety of UCB44212 as add-on therapy in subjects with focal epilepsy.
What is the current status of trial NCT00152503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2005-08-31. Estimated completion is 2006-05-12.
What conditions does trial NCT00152503 study?
This clinical trial studies the following conditions: Epilepsy, Partial.
What interventions are being tested in trial NCT00152503?
The interventions under investigation include: Seletracetam (UCB44212) (DRUG).
Who is sponsoring clinical trial NCT00152503?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00152503 being conducted?
This trial has 17 study locations across Arizona, Arkansas, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Partial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00152503's enrollment target sits among peer trials
59 1133rd of 2000 higher than 866 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI